Considerations of the effects of commonly investigated drugs for COVID-19 in the cholesterol synthesis pathway.
作者信息
Gomez Marti Juan Luis, Brufsky Adam M
机构信息
Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
UPMC Hillman Cancer Center Magee Women's Hospital Suite 4628,Pittsburgh, PA USA.
出版信息
Expert Opin Pharmacother. 2021 Jun;22(8):947-952. doi: 10.1080/14656566.2021.1897104. Epub 2021 Mar 11.
Abstract
摘要
相似文献
1
Considerations of the effects of commonly investigated drugs for COVID-19 in the cholesterol synthesis pathway.关于新冠病毒病常用研究药物在胆固醇合成途径中的作用的考量。
Expert Opin Pharmacother. 2021 Jun;22(8):947-952. doi: 10.1080/14656566.2021.1897104. Epub 2021 Mar 11.
2
Letter to the Editor in response to the article 'Candidate drugs against SARS-CoV-2 and COVID-19'.致编辑的信：回应《抗SARS-CoV-2和COVID-19的候选药物》一文
Pharmacol Res. 2021 Jan;163:105285. doi: 10.1016/j.phrs.2020.105285. Epub 2020 Nov 4.
3
Targeting Neuroinvasion by SARS-CoV-2: Emerging Trends in Drug and Antibody Delivery to Combat COVID-19.针对 SARS-CoV-2 的神经入侵：用于抗击 COVID-19 的药物和抗体递送至新兴趋势。
ACS Chem Neurosci. 2021 Jul 21;12(14):2555-2557. doi: 10.1021/acschemneuro.1c00372. Epub 2021 Jul 6.
4
Anaesthesia drugs, SARS-CoV-2, and the sigma-1 receptor: a complex affair. Comment on Br J Anaesth 2021; 127: e32-4.麻醉药物、严重急性呼吸综合征冠状病毒2（SARS-CoV-2）与σ-1受体：一个复杂的问题。对《英国麻醉学杂志》2021年；127卷：e32 - 4的评论
Br J Anaesth. 2021 Dec;127(6):e215-e218. doi: 10.1016/j.bja.2021.09.008. Epub 2021 Sep 20.
5
Are glomerular patients treated with immunosupressed drugs more protected against sever SARS-Covid -2?接受免疫抑制药物治疗的肾小球疾病患者对重症SARS-CoV-2的抵抗力是否更强？
Semin Arthritis Rheum. 2020 Dec;50(6):e4. doi: 10.1016/j.semarthrit.2020.09.004. Epub 2020 Sep 22.
6
Recent Advances on Drugs and Vaccines for COVID-19.新冠病毒药物和疫苗的最新进展
Inquiry. 2021 Jan-Dec;58:469580211055630. doi: 10.1177/00469580211055630.
7
Myotoxic drugs and immunodeficiency may contribute to the poor outcome of COVID-19 patients with myotonic dystrophy.肌毒性药物和免疫缺陷可能导致患有强直性肌营养不良的COVID-19患者预后不良。
Acta Neurol Belg. 2021 Jun;121(3):799-800. doi: 10.1007/s13760-020-01551-8. Epub 2020 Nov 23.
8
Benzodiazepine Interaction With COVID-19 Drugs.苯二氮䓬类药物与新冠病毒治疗药物的相互作用。
Prim Care Companion CNS Disord. 2021 Oct 28;23(6):21br03081. doi: 10.4088/PCC.21br03081.
9
High-throughput screening and evaluation of repurposed drugs targeting the SARS-CoV-2 main protease.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）主要蛋白酶的药物再利用的高通量筛选与评估
Signal Transduct Target Ther. 2021 Sep 29;6(1):356. doi: 10.1038/s41392-021-00763-5.
10
Update to living WHO guideline on drugs for covid-19.世界卫生组织关于新冠肺炎药物的现行指南更新。
BMJ. 2021 Jul 6;374:n1703. doi: 10.1136/bmj.n1703.
引用本文的文献
1
COVID-19 Drug Repurposing: A Network-Based Framework for Exploring Biomedical Literature and Clinical Trials for Possible Treatments.2019冠状病毒病药物重新利用：一个基于网络的框架，用于探索生物医学文献和临床试验以寻找可能的治疗方法。
Pharmaceutics. 2022 Mar 4;14(3):567. doi: 10.3390/pharmaceutics14030567.
本文引用的文献
1
Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.羟氯喹和阿奇霉素对新型冠状病毒肺炎患者严重急性呼吸综合征冠状病毒2清除率的影响：一项荟萃分析
Int J Antimicrob Agents. 2021 Jan;57(1):106240. doi: 10.1016/j.ijantimicag.2020.106240.
2
Dysregulation of the mevalonate pathway during SARS-CoV-2 infection: An in silico study.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染期间甲羟戊酸途径的失调：一项计算机模拟研究
J Med Virol. 2021 Apr;93(4):2396-2405. doi: 10.1002/jmv.26743. Epub 2020 Dec 29.
3
Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial.羟氯喹对 COVID-19 住院患者 14 天临床状态的影响：一项随机临床试验。
JAMA. 2020 Dec 1;324(21):2165-2176. doi: 10.1001/jama.2020.22240.
4
Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells.鉴定人类细胞中感染 SARS-CoV-2 所需的宿主因子。
Cell. 2021 Jan 7;184(1):92-105.e16. doi: 10.1016/j.cell.2020.10.030. Epub 2020 Oct 24.
5
COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study.COVID-19 门诊患者：锌联合小剂量羟氯喹和阿奇霉素的早期风险分层治疗：一项回顾性病例系列研究。
Int J Antimicrob Agents. 2020 Dec;56(6):106214. doi: 10.1016/j.ijantimicag.2020.106214. Epub 2020 Oct 26.
6
Reissuing the sigma receptors for SARS-CoV-2.再发行 SARS-CoV-2 的 sigma 受体。
J Clin Neurosci. 2020 Oct;80:72-73. doi: 10.1016/j.jocn.2020.08.014. Epub 2020 Aug 11.
7
Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study.使用伊维菌素与 COVID-19 住院患者的死亡率降低相关：COVID-19 中的伊维菌素研究。
Chest. 2021 Jan;159(1):85-92. doi: 10.1016/j.chest.2020.10.009. Epub 2020 Oct 13.
8
Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality.羟氯喹治疗 COVID-19 住院患者：评估死亡率的真实世界经验。
Pharmacotherapy. 2020 Nov;40(11):1072-1081. doi: 10.1002/phar.2467.
9
Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review.羟氯喹对新冠病毒病有效，且早期使用时疗效持续：一项系统评价
New Microbes New Infect. 2020 Nov;38:100776. doi: 10.1016/j.nmni.2020.100776. Epub 2020 Oct 5.
10
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.羟氯喹治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Nov 19;383(21):2030-2040. doi: 10.1056/NEJMoa2022926. Epub 2020 Oct 8.
Zotero 插件